The American Journal of Managed Care3 小时
Male Patients With Eosinophilic Esophagitis Face Higher Complication Rates
Compared with female patients, male patients with eosinophilic esophagitis have higher rates of complications, including ...
Pharmaceutical Technology1 天
MORF-057 by Eli Lilly and Co for Ulcerative Colitis: Likelihood of Approval
MORF-057 is under development for the treatment of autoimmune disorders including ulcerative colitis, Crohn's disease and eosinophilic esophagitis. It is administered orally. It is developed based on ...
Le Lézard2 天
Holoclara Selects Eosinophilic Esophagitis as its Lead Indication for HC002, a First-in ...
Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of eosinophilic esophagitis (EoE ...
gastroenterologyadvisor3 天
Once or Twice Daily Topical Steroids Yield Similar Outcomes in EoE
Topical steroids taken daily or twice daily do not result in significantly varying outcomes among individuals with ...
WOKV3 天
Join Dr. Koren, Dr Lankarani & Rich Jones On January 24th!
Join Dr Michael Koren, Rich Jones and Borland Groover’s Gastroenterologist Dr Ali Lankarani for a free luncheon, and live recording of MedEvedence in the Farah and Farah Performance studio, January ...
Eosinophilic Esophagitis Market Insight, Epidemiology And Market Forecast To 2034
The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...
19 drug approvals in 2024 that had 'big clinical impact,' according to GoodRx
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of ...
Pharmaceutical Technology7 天
IRL-201104 by Revolo Biotherapeutics for Inflammation: Likelihood of Approval
IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition ...
startupticker.ch7 天
Two Swiss biotech companies report results of Phase II clinical trials
EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, announced today that the complete results of the ACESO ...
Businessworld7 天
cricket 4k wallpaper for mobile
INR:9334. cricket 4k wallpaper for mobile Zhejiang announces the proposed winning bids for the centralized procurement of cardiothoracic surgery a ...
Businessworld7 天
Ralshree Go8
Ralshree Go8 Roche's Xolair prefilled syringe self-injection application accepted by US FDA In-depth review of Nature sub-journal: How to develop anti-agin ...
Businessworld7 天
bet builder apk
INR:9259. bet builder apk If You Are the One - Outlook for the Adjustment of the National Medical Insurance Catalogue in 2020 FDA's emergency use authorization pr ...